BCM
IGMS

Bayesian Capital Management’s IGM Biosciences IGMS Stock Holding History

Bayesian Capital Management’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-16,900
Closed -$305K – 851
2022
Q2 		$305K Buy
+16,900
New +$301K 0.06% 478

Other funds holding IGMS

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bayesian Capital Management's IGMS Position: Q3 2022 in Review

Bayesian Capital Management sold out of IGM Biosciences (IGMS) in Q3 2022, closing a stake of 16,900 shares — an estimated $305K sold.

Bayesian Capital Management first reported a position in IGMS in Q2 2022 and held it in 1 quarter. The position peaked at $305K in Q2 2022. 92 funds tracked by Wall St. Rank hold IGMS as of Q3 2022.

  • Bayesian Capital Management reported no remaining IGM Biosciences position as of Q3 2022 after selling out during the quarter.
  • Bayesian Capital Management sold 16,900 IGM Biosciences shares in Q3 2022, an estimated $305K.
  • Bayesian Capital Management first reported a position in IGM Biosciences in Q2 2022 and held it in 1 quarter.
  • Bayesian Capital Management's IGM Biosciences position peaked at $305K in Q2 2022.
  • 92 funds tracked by Wall St. Rank held IGM Biosciences as of Q3 2022.

Based on Bayesian Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.